ArticleBMJ neurology open2026
Stroke risk in patients with hypertensive retinopathy: a systematic review and meta-analysis.
Article in BMJ neurology open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hypertensive retinopathy (HTRP) is a complication of hypertension and is recognised as hypertension-mediated target-organ damage. Hypertension is also the leading risk factor for stroke. This systematic review and meta-analysis evaluated the stroke risk in patients with HTRP to determine whether HTRP is associated with stroke. Methods: PubMed, Embase, Web of Science and the Cochrane Library were searched from inception to 13 December 2025. Pooled risk ratios with 95% CIs were calculated. For the proportions of HTRP and stroke among patients with hypertension, risk differences and standard errors were calculated. Subgroup analyses were conducted according to HTRP severity (mild and severe) and stroke type (ischaemic and haemorrhagic). Results: This meta-analysis included 10 studies involving 26 776 participants. The proportions of HTRP and stroke among all the participants were 0.42 (95% CI 0.23 to 0.61) and 0.15 (0.11 to 0.18), respectively. The proportion of stroke in participants with HTRP was 0.20 (0.14 to 0.27). The pooled risk ratio for stroke in patients with HTRP compared with those without HTRP was 1.87 (1.42 to 2.45). Compared with patients with mild HTRP and those without HTRP, patients with severe HTRP had higher risk of stroke, with risk ratios of 1.88 (1.51 to 2.34) and 3.10 (1.91 to 5.05), respectively. The risk ratios for ischaemic and haemorrhagic stroke in patients with HTRP compared with those without HTRP were 1.79 (1.20 to 2.67) and 1.39 (0.86 to 2.26), respectively. Conclusions: HTRP is associated with an increased stroke risk, particularly ischaemic stroke. These findings suggest that HTRP can serve as an important biomarker for stroke-risk stratification, and that periodic retinal examinations can contribute to stroke prevention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.